Zosuquidar (LY335979) 3HCl是一种有效的P-glycoprotein(P-糖蛋白)介导的多药耐抗性的调节剂,Ki为60 nM。
别名:Zosuquidar trihydrochloride
Zosuquidar (LY335979) 3HCl是一种有效的P-glycoprotein(P-糖蛋白)介导的多药耐抗性的调节剂,Ki为60 nM。LY335979 竞争性抑制[3H]vinblastine与P-gp的平衡结合,Ki为 60 nM,通过阻断CEM/VLB100质膜中P-gp的[3H]azidopine的光亲和标记。LY335979 浓度为0.1 μM时,单独给药对药物敏感的MDR细胞系,具有细胞毒性,IC50为6 μM-16 μM,且浓度为 0.5 μM时,完全扭转对 MDR 细胞P388/ADR, MCF7/ADR, 2780AD, 或 UCLA-P3.003VLB溶瘤细胞抗性(Vinblastine, Doxorubicin, 或 Etoposide)。LY335979作用于表达P-gp的白血病细胞系,包括K562/HHT40, K562/HHT90, K562/DOX 和 HL60/DNR,显著恢复药物敏感性,且作用于携带活性P-gp的原发性AML细胞,增强蒽环类药物(Daunorubicin, Idarubicin, Mitoxantrone)和gemtuzumab ozogamicin 的毒性。
体外实验* | |
---|---|
细胞系 | MCF-7 and MCF-7/ADR cells |
方法 | Cytotoxicity Assays. Cell viability was determined using a modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide dye reduction method. Cells were harvested during logarithmic growth phase, and seeded in 96-well plates (Costar) at 7.5X104 cells/well. The cells were then cultured for 72 h in the presence of oncolytics with or without modulators. MCF-7 and MCF-7/ADR cells were incubated 24 h before the addition of the drug with and without the modulator. Modulators were prepared as 2 mM DMSO stocks and added to wells to give final concentrations ranging from 0.05 to 5 uM. After 72 h, 20 ul of freshly prepared 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyltetrazolium bromide (5 mg/mL in Dulbecco's PBS) was added to each well and incubated for 4 h in a 37°C incubator containing 5% CO2. Cells were pelleted in a Sorvall RT6000B centrifuge, 70 p.1of medium was carefully removed from each well, and 100ul of 2-propanol/0.04 N HC1 was added. Cells were resuspended 5-10 times with a Multipipettor or until no particulate matter was visible. Plates were immediately read on a Titertek Multiskan MCC/340 microplate reader Flow Laboratories (McLean, VA) with a test wavelength of 570 nm and a reference wavelength of 630 nm.Controls were measured in quadruplicate and modulators were measured in duplicate. Cytotoxicity analyses were also performed using the CeliTiter 96 AQueous assay kit (Promega Corp., Madison, WI) according to the manufacturer's instructions. |
浓度 | 0.05~5µM |
处理时间 | 72h |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
体内实验* | |
---|---|
动物模型 | P388/ADR tumors bearing mice |
配制 | stock solution was 2.5 to 5 mg/nil in 5% manrntol |
剂量 | 20 mg/kg once daily for 5 days |
给药处理 | i.v. injection |
*上述方法来自公开文献,仅供相同目的实验参考。如实验目的、材料、方法不同,请参考其他文献。
分子量 | 637.00 |
分子式 | C32H31F2N3O2.3HCl |
CAS号 | 167465-36-3 |
溶解性(25°C) | DMSO ≥35 mg/mL |
储存条件 |
粉末型式 -20°C 3年;4°C 2年 溶于溶剂 -80°C 6个月;-20°C 1个月 |
运输方式 | 冰袋运输,根据产品的不同,可能会有相应调整。 |
*下述溶液配置方法仅为基于分子量计算出的理论值。不同产品在配置溶液前,需考虑其在不同溶剂中的溶解度限制。
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.5699 mL | 7.8493 mL | 15.6986 mL |
5 mM | 0.314 mL | 1.5699 mL | 3.1397 mL |
10 mM | 0.157 mL | 0.7849 mL | 1.5699 mL |
小鼠 | 大鼠 | 兔 | 豚鼠 | 仓鼠 | 狗 | |
重量 (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
体表面积 (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
Km 系数 | 3 | 6 | 12 | 8 | 5 | 20 |
动物 A (mg/kg) = 动物 B (mg/kg) × | 动物 B的Km系数 |
动物 A的Km系数 |
例如,依据体表面积折算法,将化合物用于小鼠的剂量20 mg/kg 换算成大鼠的剂量,需要将20 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到化合物用于大鼠的等效剂量为10 mg/kg。
其他相关的P-glycoprotein产品 |
---|
Reversin 121
Reversin 121 是一种 P-糖蛋白 (P-glycoprotein) 抑制剂。 |
Reversin 205
Reversin 205 ([Boc-Glu(Obzl)]2-Lys-Ome) 是一种 P-糖蛋白 (ABCB1) 抑制剂。 |
P-gb-IN-1
P-gb-IN-1 是一种2,5-二取代呋喃衍生物,是一种高效、广谱的P-糖蛋白 (P-gp) 抑制剂。 |
P-gp inhibitor 13
P-gp inhibitor 13 是一种 P-gp 抑制剂。 |
ABCB1-IN-1
ABCB1-IN-1 是一种有效的 ABCB1 抑制剂。 |
产品仅供科学研究或药证申报的用途使用,不为任何个人或者非科研性质的其他用途提供服务。
Copyright © 2010-2022 AbMole版权所有 沪ICP备16047849号 沪公网安备 31011502012228号